CorWave: Eliminating the Drawbacks that have Hindered Ventricular Assist Devices

article image

Although LVADs have the potential to save the lives of many heart failure patients without other options, these devices have been plagued over the years by high rates of adverse events. Safety and efficacy are improving, as clinicians learn more about how to implant devices and care for patients, but newcomer CorWave believes the answer lies in a completely new technology.

Without left ventricular assist devices (LVADs), 250,000 patients in the US with advanced heart failure would face repeated hospitalizations and a greatly diminished quality of life during days that are numbered.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: